Essiac is an herbal tea formula consisting of four primary ingredients: burdock root (Arctium lappa), sheep sorrel (Rumex acetosella), slippery elm inner bark (Ulmus rubra), and Indian/Turkish rhubarb root (Rheum officinale). The name "Essiac" is the reverse spelling of Caisse — the surname of Rene Caisse, a Canadian nurse who popularised the formula from the 1920s until her death in 1978.
Flor-Essence® is a commercial eight-herb expansion of the original Essiac formula, adding blessed thistle, red clover, kelp, and watercress. It was developed after Caisse's death by Flora Inc. in Canada and is now sold globally, including widely across Ireland in health food stores. Both Essiac and Flor-Essence are positioned as general wellness tonics, immune support preparations, and — controversially in some marketing — supportive therapies for people with cancer.
Rene Caisse was a nurse working in Ontario, Canada, who claimed to have received the herbal formula from an Ojibwe (Chippewa) medicine man in the 1920s. She began administering the tea to cancer patients, claiming dramatic results. From the 1920s to the 1970s, she ran a clinic in Bracebridge, Ontario, treating thousands of patients with terminal cancer diagnoses, reportedly free of charge. Her clinic was repeatedly threatened with closure by Canadian medical authorities but attracted significant public support, petitions, and political defence.
In 1977, Caisse entered into an agreement with Resperin Corporation to conduct formal clinical trials of Essiac, coordinated with the Canadian government. The trials were judged by the Canadian Cancer Research Group as scientifically insufficient — lacking controlled design and adequate measurement — and did not provide evidence of anticancer efficacy. When Rene Caisse died in 1978 at age 90, the formula passed through various hands and eventually became the foundation for commercial products including Flor-Essence.
The US National Cancer Institute (NCI) reviewed the case records submitted by Rene Caisse and her collaborator Dr Charles Brusch in the 1980s. The review assessed patient records provided to demonstrate anticancer efficacy. The NCI's assessment was that the cases provided were insufficient to demonstrate that Essiac had any anticancer activity — the records were incomplete, diagnoses were not always confirmed by biopsy, follow-up was inadequate, and there was no control group against which to compare outcomes. Spontaneous remissions, misdiagnoses, and concurrent conventional treatment in some cases were uncontrolled confounders.
The NCI did not conduct its own clinical trial of Essiac, which remains a criticism — but neither did it find evidence in the submitted records to justify one under their standard criteria. The Canadian federal review reached similar conclusions.
In vitro studies have found that individual ingredients of Essiac/Flor-Essence demonstrate various biological activities:
Burdock root — contains arctigenin, which has shown antiproliferative activity in certain cancer cell lines in vitro. The clinical relevance of in vitro antiproliferative activity is unclear.
Sheep sorrel — contains anthraquinones and polyphenols with antioxidant properties in vitro.
Slippery elm — primarily a mucilage-forming herb with GI soothing properties; limited anticancer data.
Rhubarb root — also contains anthraquinones including emodin, which has been studied for antiproliferative effects in vitro.
However — and this is critical — the combination formula has been tested for anticancer activity in cell culture and animal models with inconsistent and sometimes contradictory results. A published study by Kulp et al. (2006) found that Flor-Essence actually stimulated the growth of oestrogen-receptor-positive breast cancer cells in culture and in an animal model. This is a concerning finding that has not been adequately addressed in the clinical literature and should give pause to anyone with hormone-sensitive cancers considering this product.
There are no published, peer-reviewed, randomised controlled trials demonstrating anticancer efficacy of either Essiac or Flor-Essence in human patients. This is the evidential bedrock: a product sold for decades with cancer associations, without a single properly designed human trial demonstrating therapeutic benefit.
A 2006 survey study by Zick et al. (Integrative Cancer Therapies) collected quality-of-life self-report data from 510 cancer patients using Essiac. Results showed no significant improvement in quality of life, cancer-specific symptoms, or physical wellbeing compared to non-users. This was an observational survey, not a controlled trial, but the direction of findings does not support the product's reputation.
| Claim | Evidence Level | Source |
|---|---|---|
| Treats or cures cancer | No Evidence | No RCT; NCI review insufficient evidence; Health Canada review negative |
| Improves quality of life in cancer patients | Not Supported | Zick et al. 2006 survey — no significant improvement |
| Anticancer activity in cell culture | In vitro only — conflicting | Some antiproliferative activity; Kulp 2006 found growth stimulation in ER+ breast cancer |
| General immune/antioxidant support | Theoretical only | Individual herb properties not specifically studied in combination |
| Safe alongside chemotherapy | Unknown — Potential Interactions | No safety studies with concurrent chemotherapy; anthraquinone content may be relevant |
This section is important, and we include it without apology. Essiac and Flor-Essence are sold in Irish health shops — including by well-intentioned retailers who genuinely believe in their benefit — to customers who often include people with cancer diagnoses. The marketing, while not explicitly claiming to cure cancer in the current Irish regulatory environment, relies on a 100-year-old story of miraculous recoveries and alternative-to-oncology positioning.
People with cancer face real distress and a natural desire to explore every possible option. This is deeply human and entirely understandable. The ethical concern is whether the Essiac/Flor-Essence evidence base — which is essentially zero for therapeutic benefit in cancer — justifies the product's implicit positioning as a cancer support supplement, particularly when there is laboratory evidence (Kulp 2006) suggesting the formula might stimulate certain cancer cell types. A well-informed decision requires access to this information, not just to the origin story.
Standard preparation involves brewing the dry herb blend as a tea, or the prepared liquid formula is diluted in hot water. Standard recommended dosing is one to two fluid ounces once to twice daily on an empty stomach. As a herbal tonic and for general wellbeing interest, this use pattern is not associated with known safety concerns in healthy adults.
The primary safety concerns with Essiac/Flor-Essence are:
Anthraquinone content — rhubarb root and sheep sorrel contain anthraquinones, which have laxative effects at high doses and can cause kidney damage with very prolonged high-dose use. Standard recommended doses are unlikely to cause toxicity in healthy adults, but prolonged heavy use should be avoided.
Oxalate content — sheep sorrel is high in oxalic acid. This may be relevant for people prone to kidney stones (oxalate type). High oxalate intake should be avoided in individuals with a history of kidney stones.
Oestrogen-sensitive conditions — the Kulp 2006 data on ER+ breast cancer cell stimulation warrants caution. People with oestrogen-sensitive cancers (breast, uterine, ovarian) should discuss this with their oncologist before using Flor-Essence or any red clover-containing preparation.
Warfarin and anticoagulants — the herbs in this formula have not been systematically studied for anticoagulant interactions. Red clover contains isoflavones and coumestans that may interact with warfarin.
Essiac and Flor-Essence have a rich, genuinely compelling human story behind them. Rene Caisse was clearly a dedicated and compassionate practitioner. But compelling stories and clinical evidence are not the same thing — and a century after the formula emerged, there are no well-designed human trials demonstrating anticancer benefit. The NCI review found insufficient evidence. The most concerning published laboratory finding (Kulp 2006) suggests a possible harm in specific cancer populations. As a general wellness tea for otherwise healthy adults with no cancer diagnosis, Essiac poses minimal safety concerns at standard doses. As a cancer treatment or support — the positioning implied by its origin story and much of its marketing — there is no evidence to support the claim, and a real reason for caution in hormone-sensitive cancer patients.